Black Diamond Therapeutics Stock is Shooting Higher Today: Here's Why
Portfolio Pulse from Vandana Singh
Black Diamond Therapeutics announced positive initial clinical data from the Phase 1 study of BDTX-1535 for non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). The drug showed clinical proof of activity in NSCLC patients and was well-tolerated. Expansion cohorts are expected to commence in H2 2023. BDTX shares are up 84.20% at $3.39.
June 27, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Black Diamond Therapeutics' BDTX-1535 shows positive initial clinical data for NSCLC and GBM, leading to an 84.20% increase in stock price.
The positive initial clinical data from the Phase 1 study of BDTX-1535 demonstrates the drug's potential in treating NSCLC and GBM. This news has led to a significant increase in Black Diamond Therapeutics' stock price, indicating a positive short-term impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100